IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rodríguez Carrio, Javier ^a   De Paz, Banesa ^a   López, Patricia ^a   Prado, Catuxa ^a   Alperi López, Mercedes ^b   Javier Ballina García, Francisco ^b   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD133 ANTIGEN; CD34 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL COUNT; CELL DAMAGE; CELL FUNCTION; CELL MATURATION; CELL POPULATION; CELL REGENERATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

ADULT; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CELL MOVEMENT; DEMOGRAPHY; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; STEM CELLS;

EID: 84908153950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086069     Document Type: Article

References (55)

1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. annrheumdis-2011-200726 [pii];10.1136/annrheumdis-2011-200726 [doi].
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, et al. (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37: 481-494. (Pubitemid 24115934)
3. Hansel S, Lassig G, Pistrosch F, Passauer J (2003) Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170: 177-180. S0021915003002818 [pii].
4. Pompilio G, Capogrossi MC, Pesce M, Alamanni F, DiCampli C, et al. (2009) Endothelial progenitor cells and cardiovascular homeostasis: clinical implications. Int J Cardiol 131: 156-167. S0167-5273(08)00949-2 [pii];10.1016/j.ijcard.2008.08.033 [doi].
5. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, et al. (2000) In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95: 3106-3112. (Pubitemid 30321161)
6. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, et al. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958. (Pubitemid 30062717)
7. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N (2006) CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 98: e20- e25. 01.RES.0000205765.28940.93 [pii];10.1161/01.RES.0000205765.28940.93 [doi].
8. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600. 10.1056/NEJMoa022287 [doi];348/7/593 [pii].
9. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, et al. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999-1007. 353/10/999 [pii];10.1056/NEJMoa043814 [doi].
10. Full LE, Ruisanchez C, Monaco C (2009) The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 11: 217. ar2631 [pii];10.1186/ar2631 [doi].
11. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963. 10.1161/01.CIR.0000099844. 31524.05 [doi];108/24/2957 [pii].
12. Dessein PH, Joffe BI, Singh S (2005) Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 7: R634-R643. ar1717 [pii];10.1186/ar1717 [doi].
13. Malarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, et al. (2008) Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart 94: 724-729. hrt.2007.119271 [pii];10.1136/hrt.2007.119271 [doi].
14. Ronnblom L (2011) The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 116: 227-237. 10.3109/03009734.2011.624649 [doi].
15. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, et al. (2007) Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110: 2907-2915. blood-2007-05- 089086 [pii];10.1182/blood-2007-05-089086 [doi].
16. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, et al. (2010) The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 185: 4457-4469. jimmunol.1001782 [pii];10.4049/jimmunol.1001782 [doi].
17. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, et al. (2012) Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 64: 2975-2985. 10.1002/art.34504 [doi].
18. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, et al. (2007) Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56: 3759-3769. 10.1002/art.23035 [doi]. (Pubitemid 350100709)
19. Kaplan MJ, Salmon JE (2011) How does interferon-alpha insult the vasculature? Let me count the ways. Arthritis Rheum 63: 334-336. 10.1002/art.30161 [doi].
20. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, et al. (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45: 694-702. kei244 [pii];10.1093/rheumatology/kei244 [doi].
21. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, et al. (1999) ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26: 705-711. (Pubitemid 29125596)
22. Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22: 6A-13A. (Pubitemid 23285789)
23. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. (2011) TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216: 125-130. S0021-9150(11)00192-4 [pii];10.1016/j.atherosclerosis.2010.10.052 [doi].
24. Rodriguez-Carrio J, Prado C, de PB, Lopez P, Gomez J, et al. (2012) Circulating endothelial cells and their progenitors in systemic lupus erythematosus and early rheumatoid arthritis patients. Rheumatology (Oxford) 51: 1775-1784. kes152 [pii];10.1093/rheumatology/kes152 [doi].
25. Distler JH, Allanore Y, Avouac J, Giacomelli R, Guiducci S, et al. (2009) EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 68: 163-168. ard.2008.091918 [pii];10.1136/ard.2008.091918 [doi].
26. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102: 3372-3377. 0408506102 [pii];10.1073/pnas.0408506102 [doi].
27. Cantaert T, Baeten D, Tak PP, van Baarsen LG (2010) Type I IFN and TNFalpha cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 12: 219. ar3150 [pii];10.1186/ar3150 [doi].
28. Higgs BW, Liu Z, White B, Zhu W, White WI, et al. (2011) Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70: 2029-2036. ard.2011.150326 [pii];10.1136/ard.2011.150326 [doi].
29. Reynier F, Petit F, Paye M, Turrel-Davin F, Imbert PE, et al. (2011) Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One 6: e24828. 10.1371/journal.-pone.0024828 [doi];PONE-D-11-05657 [pii].
30. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 66: 1008-1014. ard.2006.063412 [pii];10.1136/ard.2006.063412 [doi].
31. Egan CG, Caporali F, Garcia-Gonzalez E, Galeazzi M, Sorrentino V (2008) Endothelial progenitor cells and colony-forming units in rheumatoid arthritis: association with clinical characteristics. Rheumatology (Oxford) 47: 1484-1488. ken299 [pii];10.1093/rheumatology/ken299 [doi].
32. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, et al. (2005) Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111: 204-211. 01.CIR.0000151875.21836.AE [pii];10.1161/01.CIR.0000151875.21836.AE [doi].
33. Herbrig K, Haensel S, Oelschlaegel U, Pistrosch F, Foerster S, et al. (2006) Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 65: 157-163. ard.2005.035378 [pii];10.1136/ard.2005.035378 [doi].
34. Allanore Y, Batteux F, Avouac J, Assous N, Weill B, et al. (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25: 60-66. 1982 [pii].
35. Jodon dV, V, Avouac J, Ponceau A, Ruiz B, Kahan A, et al. (2010) Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. Arthritis Res Ther 12: R27. ar2934 [pii];10.1186/ar2934 [doi].
36. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, et al. (2010) Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatol 37: 529-535. jrheum.090782 [pii];10.3899/jrheum.090782 [doi].
37. Kerola AM, Kauppi MJ, Kerola T, Nieminen TV (2012) How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis 71: 1606-1615. annrheumdis-2012-201334 [pii];10.1136/an-nrheumdis- 2012-201334 [doi].
38. Kirou KA, Lee C, George S, Louca K, Peterson MG, et al. (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52: 1491-1503. 10.1002/art.21031 [doi]. (Pubitemid 40663941)
39. Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, et al. (2010) Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 49: 156-166. kep345 [pii];10.1093/rheumatology/kep345 [doi].
40. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, et al. (2006) Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3: e491. 05-PLME-RA-0506R3 [pii];10.1371/journal.pmed.0030491 [doi].
41. Kirou KA, Cole P, Salmon JE, Roman MJ, Crow MK (2013) Identification of molecular pathways associated with progression of carotid atherosclerosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 54: suppl:S807.
42. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, et al. (2012) Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 7: e37000. 10.1371/journal.pone.0037000 [doi];PONE-D-12-02237 [pii].
43. Zhao W, Somers EC, McCune WJ, Kaplan MJ (2009) Type I Interferon gene signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 60: suppl 10: 582.
44. Kobayashi T, Sato Y, Hasegawa Y, Nagasawa T, Yoda Y, et al. (1992) Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon. Intern Med 31: 936-940.
45. Kuwata A, Ohashi M, Sugiyama M, Ueda R, Dohi Y (2002) A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. Am J Med Sci 324: 331-334. (Pubitemid 36109326)
46. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331-2337. (Pubitemid 32977500)
47. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, et al. (1995) Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 38: 96-104.
48. Lacki JK, Samborski W, Mackiewicz SH (1997) Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 16: 275-278. (Pubitemid 27273174)
49. Lopez P, Gomez J, Prado C, Gutierrez C, Suarez A (2008) Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 35: 1559-1566. 08/13/0621 [pii].
50. Weckerle CE, Mangale D, Franek BS, Kelly JA, Kumabe M, et al. (2012) Large-scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum 64: 2947-2952. 10.1002/art.34483 [doi].
51. Kariuki SN, Crow MK, Niewold TB (2008) The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 58: 2818-2823. 10.1002/art.23728 [doi].
52. Deng XL, Li XX, Liu XY, Sun L, Liu R (2010) Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage. Rheumatol Int 30: 1429-1436. 10.1007/s00296-009-1156-4 [doi].
53. Grisar J, Steiner CW, Bonelli M, Karonitsch T, Schwarzinger I, et al. (2008) Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) 47: 1476-1483. ken286 [pii];10.1093/rheumatology/ken286 [doi].
54. van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, et al. (2010) Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 12: R11. ar2912 [pii];10.1186/ar2912 [doi].
55. Yao Y, Richman L, Higgs BW, Morehouse CA, de los RM, et al. (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60: 1785-1796. 10.1002/art.24557 [doi].